This latest settlement brings the total paid by Eli Lilly to resolve lawsuits involving Zyprexa to more than $1.2 billion. Manufactured by Eli Lilly, Zyprexa has become a popular anti-psychotic drug because it does not produce the “Parksion’s-like” side effects associated with other medicines used to treat mental illness. Eli Lilly reently agreed to pay up to $500 million to settle claims relating to Zyprexa. ZYPREXA is used for the treatment of psychotic conditions such as schizophrenia and bipolar disorder. "While the tribunal can only award damages and can't force Canada to change its laws, some argue that the latter is, ultimately, what Eli Lilly is after.The company's so-called investor-state challenge "marks the first attempt by a patent-holding pharmaceutical corporation to use the extraordinary investor privileges provided by U.S. 'trade' agreements as a tool to push for greater monopoly patent protections, which increase the cost of medicines for consumers and governments," Public Citizen said.If Eli Lilly is successful in getting the NAFTA tribunal to approve its claim for compensation, it "could expose Canada to a slew of investor-state attacks from other drug companies that have had patents invalidated because their patent applications failed to show or predict that the medicines would provide the promised benefits," the group said.Kazi Stastna is a senior producer with CBCNews.ca. LEARN MORE ABOUT US, AND HOW YOU CAN HELP.Judge Rescinds Injunction Against Wiki, Other Websites New York - A U.S. District Court judge today refused Eli Lilly's request to ban a number of websites from publishing leaked documents relating to Zyprexa, Eli Lilly's top-selling drug. Eli Lilly alleges Canada violated the provisions of Chapter 11 that guarantee fair and equal treatment to foreign investors and protect them from expropriation of their investments. "A Federal Court decision in 2010 invalidated Eli Lilly's patent for Strattera (atomoxetine), a drug used to treat attention deficit hyperactivity disorder (ADHD), six years before it was due to expire.Federal Court decisions in 2009 and 2011 voided the patent for Zyprexa (olanzapine), an anti-psychotic drug used to treat schizophrenia, which was to expire in April 2011.The challenges to both patents were initiated by the generic drug company Novopharm (later renamed Teva Canada Ltd.).In the Straterra case, the Federal Court judge found that the drug did not meet the threshold of "utility" for the long-term treatment of ADHD and did not fulfil the implied "inventive promise" of the patent — that is, it did not do what the inventor said, or implied, it would do when it applied for the patent.The court found that the clinical trial used to demonstrate the drug's utility — a seven-week, double-blind placebo-controlled study of 22 patients — was "too small and too short in duration to provide anything more than interesting but inconclusive data. Prior to that, she was a reporter and editor in Montreal, Germany and the Czech Republic. Chat with us. 1-800-LILLYRX 1-800-545-5979. Information Request. For information on Zyprexa side effects and this lawsuit please visit www.zyprexa-side-effects.com. Recently In The News; Press Releases; Resources. She has worked as a features writer and copy editor with CBC's digital news team for 10 years. Or you can. Since its approval, the drug has become Eli Lilly’s best selling drug. "Patent decisions in Canada over the last decade not only fly in the face of long-established international standards, but they're subjective and completely unpredictable," Doug Norman, vice-president and general patent counsel for Eli Lilly, said in a statement issued Friday.